Brassinin
Based on 2 publication(s) in Google Scholar
Brassinin is an indole derivative found in cruciferous plants. Brassinin acts as an IDO inhibitor (Ki = 97.7 μM). Brassinin inhibits angiogenesis and induces apoptosis, autophagy, paraptosis, ROS production, and ER stress. Brassinin selectively stimulates lysosomal degradation of Tie2 and promotes lysosomal and proteasomal degradation of FGFR1 in endothelial cells, downregulating AKT and ERK phosphorylation. Brassinin inhibits endothelial cell proliferation, migration, tube formation, spheroid sprouting, and angiogenesis. Brassinin inhibits PI3K/Akt/mTOR/S6K1 signaling, upregulates p21 and p27, and induces G1 phase cell cycle arrest through RB hypophosphorylation. Brassinin inhibits tyrosinase catalytic activity, reduces tyrosinase mRNA, and inhibits MITF nuclear translocation. Brassinin is used for research on triple-negative breast cancer, chronic myeloid leukemia, colon cancer, glioma, atherosclerosis, and skin cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.80%
- CAS. Nr.: 105748-59-2
- Formel: C11H12N2S2
- Molecular Weight:236.37
-
Speicherung:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Brassinin
MoreAlle Endogenous Metabolite Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[5]|
IDO 97.7 μM (Ki) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| LN-229 | IC50 |
200.8 μM
|
Antiproliferative activity against human LN229 glioma cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay.
Antiproliferative activity against human LN229 glioma cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay.
|
42674968 |
| U-373MG ATCC | IC50 |
325.6 μM
|
Antiproliferative activity against human U373 glioma cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay.
Antiproliferative activity against human U373 glioma cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay.
|
42674968 |
| T98G | IC50 |
236.7 μM
|
Antiproliferative activity against human T98G glioma cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay.
Antiproliferative activity against human T98G glioma cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay.
|
42674968 |
In Vitro
Brassinin (2.5-100 µM; 48 h) preferentially reduces the viability of HUVECs and HDMECs compared with pericytes, fibroblasts, and breast cancer cells[1].
Brassinin (25-100 µM; 6 h, then additional 18 h with BrdU (5-BrdU) (HY-15910)) inhibits HUVEC proliferation in a dose-dependent manner[1].
Brassinin (25-100 µM; 24 h) inhibits HUVEC migration in a dose-dependent manner[1].
Brassinin (25-100 µM; 24 h) inhibits HUVEC tube formation, causing a 78% reduction in tube network structures at 100 µM[1].
Brassinin (25-100 µM; 24 h) inhibits HUVEC spheroid sprouting in a dose-dependent manner[1].
Brassinin (25-100 µM; 2 h) selectively downregulates Tie2 and FGFR1 protein levels in HUVECs and inhibits AKT and ERK phosphorylation[1].
Brassinin promotes the degradation of Tie2 and FGFR1 proteins in HUVECs, with only a slight effect on Tie2 mRNA and no effect on FGFR1 mRNA[1].
Brassinin (100-400 μM; 24 h) does not affect basal proliferation but significantly reverses Ang II (Angiotensin II human) (HY-13948)-induced proliferation of mouse aortic SMCs[6].
Brassinin (100 μM; 24 h) significantly attenuates Ang II-induced migration of mouse aortic SMCs without affecting basal migration[6].
Brassinin (100 μM; 24 h) reverses the Ang II-induced decrease in SM α-actin and calponin expression in mouse aortic SMCs[6].
Brassinin (100 μM; 24 h) significantly upregulates CSE protein expression in mouse aortic SMCs without affecting 3-MST levels[6].
Brassinin (100 μM; 24 h) significantly induces CSE mRNA levels in mouse aortic SMCs[6].
Brassinin (100 μM; 24 h) significantly enhances the binding of C/EBPβ to the CSE promoter in mouse aortic SMCs[6].
Brassinin stimulates lysosomal degradation of Tie2 and both lysosomal and proteasomal degradation of FGFR1 in HUVECs[1].
Brassinin (10-100 µM; 24 h) exhibits cytotoxicity against KBM5, KCL22, and LAMA84 CML cells, while showing low cytotoxicity toward PBMCs[2].
Brassinin (50 µM; 24 h) reduces the viability of CML cells[2].
Brassinin (10-100 µM; 24 h) activates the MAPK signaling pathway in KBM5, K562, KCL22, and LAMA84 CML cells[2].
Brassinin (200 µM or higher; 24-72 h) inhibits the growth of human colon cancer HT-29 cells in a dose- and time-dependent manner[3].
Brassinin (1-15 µM; 1 h pretreatment; 6 days stimulation) inhibits α-MSH (HY-P0252)-induced melanin accumulation in B16F10 cells[7].
Brassinin (5-15 µM; 1 h pretreatment; 6 days stimulation) decreases cellular tyrosinase activity in α-MSH-stimulated B16F10 cells[7].
Brassinin (5-15 µM; 1 h pretreatment; 6 days stimulation) decreases tyrosinase mRNA levels in α-MSH-stimulated B16F10 cells[7].
Brassinin (5-15 µM; 1 h pretreatment; 6 days stimulation) inhibits the nuclear translocation of MITF in α-MSH-stimulated B16F10 cells[7].
Brassinin (100-400 μM; 48 h) exhibits antiproliferative effects in U373, T98G, LN229, GBM-Y2, and GBM-Y5 glioma cells, with IC50 values ranging from 200.8 to 547.5 μM at 48 h, but shows lower toxicity in normal HA1800 astrocytes[8].
Brassinin (25-200 μM; 48 h) inhibits clonogenic proliferation of U373, LN229, and GBM-Y2 glioma cells[8].
Brassinin (50-200 μM) inhibits the activity of the AMPKα-ULK1-beclin1 signaling pathway in U373 and LN229 glioma cells in a dose-dependent manner[8].
Brassinin (10-50 µM; 24 h) induces apoptosis, autophagy, and paraptosis markers in KBM5, K562, KCL22, and LAMA84 CML cells[2].
Brassinin (50 µM; 24 h) increases the sub G1 phase cell population in CML cells[2].
Brassinin (200-400 µM; 24 h) induces G1 phase arrest in human colon cancer HT-29 cells, with the maximum arrest effect observed at 300 µM[3].
Brassinin (50-400 µM; 6-24 h) upregulates p21 and p27 proteins and inhibits RB protein phosphorylation in human colon cancer HT-29 cells[3].
Brassinin (50-400 µM; 3-24 h) increases the amount of p21 mRNA in human colon cancer HT-29 cells by stabilizing p21 mRNA[3].
Brassinin (300-400 µM; 24 h) at least partially contributes to its induced G1 phase arrest in HT-29 cells through the increase of p27 and/or p21[3].
Brassinin (300-400 µM) induces G1 phase arrest in HT-29 cells, which involves the inhibition of the PI3K-Akt pathway[3].
Brassinin (50-400 µM; 24 h) inhibits the PI3K-Akt signaling pathway in human colon cancer HT-29 cells, as evidenced by decreased phosphorylation levels of Akt, PDK1, and GSK-3β[3].
Brassinin (50-200 μM; 48 h) blocks cell cycle progression by arresting U373 and GBM-Y2 glioma cells in the G1 phase[8].
Brassinin (50 µM; 24 h) promotes early apoptosis in KBM5, K562, KCL22, and LAMA84 CML cells[2].
Brassinin (50 µM; 24 h) induces autophagy in CML cells[2].
Brassinin (50-200 μM) inhibits autophagosome formation in U373 and LN229 glioma cells, manifested as decreased LC3-II levels and increased p62 levels[8].
Brassinin (50 µM; 12 h) induces ROS production in KBM5, K562, KCL22, and LAMA84 CML cells[2].
Brassinin (50 µM; 24 h) causes GSH/GSSG imbalance in KBM5, K562, KCL22, and LAMA84 CML cells[2].
Brassinin (50-200 μM; 48 h) induces excessive ROS production in U373 and LN229 glioma cells in a dose-dependent manner[8].
Brassinin (50 µM; 24 h) causes loss of mitochondrial membrane potential in KBM5, K562, KCL22, and LAMA84 CML cells[2].
Brassinin (50 µM; 24 h) induces ER stress and vacuolization in KBM5, K562, KCL22, and LAMA84 CML cells[2].
Brassinin (200-400 μM; 60 min) is a moderate competitive inhibitor of purified recombinant human IDO at 37 °C, with a Ki of 97.7 μM[5].
Brassinin (5-30 µM; 30 min) inhibits mushroom tyrosinase activity in a cell-free system[7].
Brassinin binds to the active site of tyrosinase with a docking score of -6.7 kcal/mol, acting as a potent tyrosinase inhibitor[7].
Brassinin (100 μM; 24 h) effectively attenuates Ang II-induced oxidative stress in mouse aortic SMCs without affecting basal ROS levels[6].
Brassinin (1-50 µM; 4 min) exhibits antioxidant activity in cell-free FRAP assays[7].
Brassinin (100 μM; 24 h) attenuates Ang II-induced upregulation of TNFα and IL6 and inhibits IL2 mRNA levels in mouse aortic SMCs[6].
Brassinin (5-20 µM; 30 min) inhibits TNF-α-induced IL-8 mRNA expression in HUVECs in a dose-dependent manner[9].
Brassinin (100 μM; 24 h) specifically reverses Ang II-induced AT1R mRNA expression without affecting AT2R, ACE, or ACE2 in mouse aortic SMCs[6].
Brassinin (50-200 μM; 48 h) promotes apoptosis in U373 and LN229 glioma cells in a dose-dependent manner[8].
Brassinin (50-200 μM) induces G1 phase arrest in U373 and LN229 glioma cells by regulating cell cycle regulatory proteins, and alters apoptosis-related protein expression to promote apoptosis[8].
Brassinin (100-200 μM; 48 h) inhibits autophagic flux in U373 and LN229 glioma cells[8].
Brassinin (1-20 µM; 30 min) inhibits TNF-α-induced adhesion of U937 monocytes to HUVECs in a dose-dependent manner[9].
Brassinin (1-20 µM; 30 min) inhibits TNF-α-induced protein expression of VCAM-1, ICAM-1, and E-selectin in HUVECs[9].
Brassinin (5-20 µM; 30 min) inhibits TNF-α-induced nuclear translocation of NF-κB p65 and increases cytoplasmic IκB-α levels in HUVECs[9].
Brassinin (1-20 µM; 30 min) inhibits TNF-α-induced cell surface expression of VCAM-1, ICAM-1, and E-selectin in HUVECs in a dose-dependent manner[9].
Brassinin (30 min) reduces TNF-α-induced intracellular ROS production in HUVECs[9].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HUVECs, HDMECs, hPC-PLs, NHDFs, MCF-7, MDA-MB-231, 4T1
-
Concentration:2.5-100 µM
-
Incubation Time:48 h
-
Result:Significantly reduced the viability of HUVECs and HDMECs.
Did not affect the viability of pericytes (hPC-PLs), fibroblasts (NHDFs), and breast cancer cells (MCF-7, MDA-MB-231, and 4T1).
-
Cell Line:HUVECs
-
Concentration:25, 50, and 100 µM
-
Incubation Time:6 h, then additional 18 h with BrdU
-
Result:Significantly inhibited EC proliferation in a dose-dependent manner.
-
Cell Line:HUVECs
-
Concentration:25, 50, and 100 µM
-
Incubation Time:24 h
-
Result:Markedly and dose-dependently reduced the number of migrated HUVECs.
-
Cell Line:HUVECs
-
Concentration:25, 50, and 100 µM
-
Incubation Time:2 h
-
Result:Significantly suppressed the phosphorylation of both AKT and ERK.
Selectively reduced the expression of Tie2 and FGFR1, but not VEGFR1 and VEGFR2.
-
Cell Line:KBM5, K562, KCL22, LAMA84, and PBMCs
-
Concentration:10, 15, 30, 50, 100 µM
-
Incubation Time:24 h
-
Result:Suppressed the viability of KBM5, KCL22, and LAMA84 cells.
Slightly affected K562 cells.
Exhibited less than 10% cytotoxicity against PBMCs at a concentration up to 50 µM.
-
Cell Line:KBM5, K562, KCL22, and LAMA84
-
Concentration:10, 30, 50 µM
-
Incubation Time:24 h
-
Result:Stimulated apoptosis and autophagy by promoting PARP cleavage and increasing LC3 expression.
Caused paraptosis by downregulating the expression of Alix.
-
Cell Line:CML cells
-
Concentration:50 µM
-
Incubation Time:24 h
-
Result:Attenuated the viability of the CML cells.
-
Cell Line:CML cells
-
Concentration:50 µM
-
Incubation Time:24 h
-
Result:Enhanced the distribution of the cells in the sub G1 phase.
-
Cell Line:KBM5, K562, KCL22, and LAMA84
-
Concentration:50 µM
-
Incubation Time:24 h
-
Result:Showed an increased concentration in the early apoptosis stage.
-
Cell Line:CML cells
-
Concentration:50 µM
-
Incubation Time:24 h
-
Result:Markedly increased the percentage of the autophagosome-stained cells.
-
Cell Line:KBM5, K562, KCL22, and LAMA84
-
Concentration:50 µM
-
Incubation Time:24 h
-
Result:Indicated that vacuolization was obtained primarily from the ER.
Induced a marked expression of ATF4 and CHOP.
-
Cell Line:KBM5, K562, KCL22, and LAMA84
-
Concentration:50 µM
-
Incubation Time:24 h
-
Result:Observed depletion of GSH.
Increased GSSG and GSSG/GSH ratio, indicating the existence of oxidative stress.
-
Cell Line:KBM5, K562, KCL22, and LAMA84
-
Concentration:10, 15, 30, 50, 100 µM
-
Incubation Time:24 h
-
Result:Significantly increased the phosphorylation of JNK, p38, and ERK.
-
Cell Line:HT-29
-
Concentration:200 µM; 300 µM; 400 µM
-
Incubation Time:24 h
-
Result:Increased cells at G1 phase from 36.2% (DMSO control) to 50.1%, 72.9%, and 55.1% with 200, 300, and 400 µM brassinin, respectively.
-
Cell Line:HT-29
-
Concentration:50-400 µM
-
Incubation Time:24 h
-
Result:Decreased phosphorylated Akt expression remarkably.
Decreased phosphorylation of PDK1 but did not change phosphorylation of PTEN.
Decreased phosphorylation of GSK-3β.
-
Cell Line:Mouse aortic vascular smooth muscle cells (SMCs)
-
Concentration:100 μM (alone); 100 μM (with 30 nM Ang II); 200-400 μM (alone)
-
Incubation Time:24 h
-
Result:Had no significant effect on basal SMC proliferation at 100 μM.
Reduced cell proliferation at 200, 300, and 400 μM.
Reversed the increased SMC proliferation stimulated by 30 nM Ang II at 100 μM.
-
Cell Line:Mouse aortic vascular smooth muscle cells (SMCs)
-
Concentration:100 μM
-
Incubation Time:24 h
-
Result:Reversed Ang II-stimulated migration.
Had no impact on basal cell migration.
Ang II alone increased migration by approximately 2.6-fold.
-
Cell Line:Mouse aortic vascular smooth muscle cells (SMCs)
-
Concentration:100 μM
-
Incubation Time:24 h
-
Result:Restored the expression of SM α-actin and calponin that were downregulated by Ang II.\n
Significantly upregulated CSE protein expression compared to the control group.
Did not alter the protein level of 3-MST.
-
Cell Line:Mouse aortic vascular smooth muscle cells (SMCs)
-
Concentration:100 μM
-
Incubation Time:24 h
-
Result:Markedly reduced the fluorescent intensity brought up by Ang II.
Had no impact on basal oxidative stress levels.
-
Cell Line:Mouse aortic vascular smooth muscle cells (SMCs)
-
Concentration:100 μM
-
Incubation Time:24 h
-
Result:Attenuated Ang II-induced upregulation of TNFα and IL6 mRNA levels.
Suppressed IL2 mRNA levels both in the presence and absence of Ang II.
Had no effect on IL4 mRNA expression.\nReversed Ang II-induced increase in AT1R mRNA levels with no significant effect on AT2R expression.
Did not alter the mRNA expression of ACE or ACE2.\n
Markedly induced CSE mRNA levels compared to control.
Ang II alone did not significantly alter CSE gene expression.
-
Cell Line:B16F10
-
Concentration:5 µM; 15 µM
-
Incubation Time:1 h pretreatment; 6 days stimulation
-
Result:Significantly reduced the mRNA level of tyrosinase among TRP-1, TRP-2, and tyrosinase genes.
-
Cell Line:B16F10
-
Concentration:5 µM; 15 µM
-
Incubation Time:1 h pretreatment; 6 days stimulation
-
Result:Inhibited MITF translocation into the nucleus compared with α-MSH-only treated cells.
-
Cell Line:U373, T98G, LN229, GBM-Y2, GBM-Y5, HA1800
-
Concentration:100-400 μM (48 h); 200 μM (24-96 h)
-
Incubation Time:48 h; 0-96 h
-
Result:Reduced the viability of U373, T98G, LN229, GBM-Y2, and GBM-Y5 cells in a concentration-dependent manner.
Exhibited minimal effect on the viability of HA1800 astrocytes.
Achieved IC50 values at 48 h for LN229: 200.8 μM, U373: 325.6 μM, T98G: 236.7 μM, GBM-Y2: 260.1 μM, and GBM-Y5: 547.5 μM.
Demonstrated a time-dependent inhibitory effect on glioma cell viability.
-
Cell Line:U373, LN229, GBM-Y2
-
Concentration:25 μM; 50 μM; 100 μM; 200 μM
-
Incubation Time:48 h
-
Result:Inhibited the proliferation of U373, LN229, and GBM-Y2 cells.
-
Cell Line:U373, GBM-Y2
-
Concentration:50, 100, 200 μM
-
Incubation Time:48 h
-
Result:Increased the percentage of cells in the G1 phase and decreased the percentage of cells in the S phase for U373 and GBM-Y2 cells.
Induced a marked increase in the percentage of U373 cells in the sub-G1 phase.
-
Cell Line:U373, LN229
-
Concentration:50, 100, 200 μM
-
Incubation Time:48 h
-
Result:Increased the percentage of apoptotic and sub-G1-phase cells in a concentration-dependent manner in U373 and LN229 cells.
-
Cell Line:U373, LN229
-
Concentration:100, 200 μM
-
Incubation Time:48 h
-
Result:Significantly reduced the number of LC3-positive puncta in U373 cells compared to untreated cells.
Decreased the number of LC3-positive puncta in LN229 cells.
-
Cell Line:U373, LN229
-
Concentration:100 μM
-
Incubation Time:48 h
-
Result:Inhibited cell proliferation, which was reversed (at least in part) by NAC in U373 cells and LN229 cells.
-
Cell Line:U373, LN229
-
Concentration:100 μM
-
Incubation Time:48 h
-
Result:Decreased LC3-II levels and increased p62 levels, which were reversed by the addition of NAC.
Reductions in p-AMPKα and beclin1 levels were reversed by NAC, but not p-ULK1 levels.
-
Cell Line:U373
-
Concentration:100 μM
-
Incubation Time:48 h
-
Result:Reduced the levels of CDK4/6 and Bcl-2, and increased the levels of p53, cleaved PARP, and Bax; these changes were rescued by NAC.
-
Cell Line:U373, LN229
-
Concentration:200 μM
-
Incubation Time:48 h
-
Result:Reduced viability, which was significantly rescued in the presence of rapamycin in U373 cells and LN229 cells.
Induced apoptosis that was partially reversed by rapamycin treatment in U373 and LN229 cells.
-
Cell Line:HUVECs
-
Concentration:1, 5, 10, 20 µM (brassinin); 10 ng/mL (TNF-α)
-
Incubation Time:30 min (brassinin pretreatment); 6 h (TNF-α stimulation)
-
Result:Inhibited TNF-α-induced VCAM-1, ICAM-1, and E-selectin protein expression levels.
-
Cell Line:HUVECs
-
Concentration:5, 10, 20 µM (brassinin); 10 ng/mL (TNF-α)
-
Incubation Time:30 min (brassinin pretreatment); 6 h (TNF-α stimulation)
-
Result:Increased cytoplasmic IκB-α levels.
Decreased cytoplasmic NF-κB p65 levels and increased nuclear NF-κB p65 levels.
-
Cell Line:HUVECs
-
Concentration:5, 10, 20 µM (brassinin); 10 ng/mL (TNF-α)
-
Incubation Time:30 min (brassinin pretreatment); 6 h (TNF-α stimulation)
-
Result:Markedly abrogated TNF-α-induced IL-8 mRNA expression in a dose-dependent manner.
In Vivo
Brassinin (180 mg/kg; i.p.; once daily; 14 days) significantly reduces TNBC tumor size and microvessel density while decreasing tumor cell proliferation without affecting apoptosis[1].
Brassinin (75 mg/kg; i.p.; 5 days/week; 2 weeks) suppresses glioma growth in a subcutaneous xenograft model, reducing tumor volume and weight, inhibiting proliferation, and decreasing Bcl-2, p-AMPKα, and beclin1 signaling with good safety[8].
Brassinin (75 mg/kg; i.p.; 5 days/week; 3 weeks) inhibits glioma growth in an intracranial xenograft model and extends the median survival of tumor-bearing mice from 29.5 days to 33.5 days[8].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c mice (8-10 weeks old)[1]
-
Dosage:100 µM
-
Administration:s.c.; single administration
-
Result:Reduced microvessel density by 40% compared to vehicle-treated controls.
-
Animal Model:Balb/c mice (female, 12-15 weeks old)[1]
-
Dosage:180 mg/kg
-
Administration:i.p.; once daily; 14 days
-
Result:Significantly reduced tumor size on day 10 and 14 after spheroid transplantation.
Markedly reduced functional microvessel density between day 3 and 14.
Significantly decreased centerline red blood cell velocity and volumetric blood flow of tumor microvessels on day 10 and 14.
Showed significantly smaller tumor size, lower microvessel density, and a decreased number of Ki67-positive proliferating tumor cells, but no change in cleaved caspase-3-positive apoptotic cells.
No difference in tumor microvessel diameter or body weight was observed.
-
Animal Model:BALB/c nude mice (18-22 g)[8]
-
Dosage:75 mg/kg
-
Administration:i.p.; 5 days/week; 2 weeks
-
Result:Reduced tumor volume from day 8 onwards.
Significantly reduced tumor weight on day 14.
Decreased the number of Ki67-positive cells.
Markedly reduced signals of Bcl-2, p-AMPKα, and beclin1.
-
Animal Model:BALB/c nude mice (18-22 g)[8]
-
Dosage:75 mg/kg
-
Administration:i.p.; 5 days/week; 3 weeks
-
Result:Significantly reduced tumor size.
Inhibited tumor proliferation.
Extended median survival from 29.5 days to 33.5 days.
Chemical Information
-
CAS. Nr. 105748-59-2
-
Appearance Powder
-
Molecular Weight 236.37
-
Formel C11H12N2S2
-
Color Off-white to light yellow
-
SMILES
S=C(NCC1=CNC2=CC=CC=C21)SC
-
Synonyms
Brassinine
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
ACS Environ Au
Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]2025 Aug 5;5(6):573-582. PMID: 41277996 -
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 50 mg/mL (211.53 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 1.25 mg/mL (5.29 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1.25 mg/mL (5.29 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protokoll
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cytoplasmic-Nuclear Fractionated Protein Extraction
Cytoplasmic-nuclear fractionated protein extraction separates soluble cytoplasmic proteins from nuclear-enriched proteins by mild plasma-membrane permeabilization, differential centrifugation, washing of nuclei, and extraction of nuclear proteins for downstream immunoblotting or related molecular analysis. The readout is the relative abundance of a protein in cytoplasmic and nuclear fractions, commonly assessed by western blotting together with compartment markers such as tubulin or pyruvate kinase for cytoplasm and lamin, nucleoporin, hnRNP, H2AX, or Lamin B for nuclear fractions.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Reinheit & Dokumentation
-
Data Sheet (338 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.2307 mL | 21.1533 mL | 42.3066 mL | 105.7664 mL |
| 5 mM | 0.8461 mL | 4.2307 mL | 8.4613 mL | 21.1533 mL | |
| 10 mM | 0.4231 mL | 2.1153 mL | 4.2307 mL | 10.5766 mL | |
| 15 mM | 0.2820 mL | 1.4102 mL | 2.8204 mL | 7.0511 mL | |
| 20 mM | 0.2115 mL | 1.0577 mL | 2.1153 mL | 5.2883 mL | |
| 25 mM | 0.1692 mL | 0.8461 mL | 1.6923 mL | 4.2307 mL | |
| 30 mM | 0.1410 mL | 0.7051 mL | 1.4102 mL | 3.5255 mL | |
| 40 mM | 0.1058 mL | 0.5288 mL | 1.0577 mL | 2.6442 mL | |
| 50 mM | 0.0846 mL | 0.4231 mL | 0.8461 mL | 2.1153 mL | |
| 60 mM | 0.0705 mL | 0.3526 mL | 0.7051 mL | 1.7628 mL | |
| 80 mM | 0.0529 mL | 0.2644 mL | 0.5288 mL | 1.3221 mL | |
| 100 mM | 0.0423 mL | 0.2115 mL | 0.4231 mL | 1.0577 mL |
Keywords
- Brassinin
- 105748-59-2
- Brassinine
- Endogenous Metabolite
- Indoleamine 2,3-Dioxygenase (IDO)
- Apoptosis
- Autophagy
- Paraptosis
- Reactive Oxygen Species (ROS)
- Tie
- Akt
- PERK
- PI3K
- mTOR
- Ribosomal S6 Kinase (RSK)
- autophagy
- apoptosis
- glioma
- angiogenesis inhibitor
- endothelial cells
- colon cancer
- paraptosis
- HUVECs
- IDO inhibitor
- chronic myelogenous leukemia
- Inhibitor
- inhibitor
- inhibit